CD38 and Miyoshi myopathy: The use of monoclonal antibodies (mAb) in the treatment of patients with MM has become ubiquitous, and based upon impressive data in the frontline setting by adding daratumumab to standard therapies87–90, many experts have recommended that a CD38 mAb be added to standard induction regimens.